Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

被引:641
作者
Halfdanarson, T. R. [1 ]
Rabe, K. G.
Rubin, J. [1 ]
Petersen, G. M.
机构
[1] Mayo Clin, Coll Med, Div Med Oncol, Rochester, MN USA
关键词
epidemiology; incidence; islet cell tumors; pancreatic neuroendocrine tumors;
D O I
10.1093/annonc/mdn351
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms that can present with symptoms of hormone overproduction. We evaluated the incidence, prognosis, and temporal trends of PNETs. Patients and methods: We analyzed all cases of PNETs registered in the Surveillance, Epidemiology, and End Results database from 1973 to 2000. Age-adjusted incidence and survival rates were calculated and survival trends over time were evaluated. Results: We identified 1483 cases of PNETs. The crude annual incidence per 1 000 000 was 1.8 in females and 2.6 in males and increased with advancing age. The incidence increased over the study period. Most patients (90.8%) had nonfunctional tumors. Advanced stage, higher grade, and age were the strongest predictors of worse survival. Patients with functional tumors had better outcomes than patients with nonfunctional tumors in both univariate and multivariate analysis (P = 0.004). Survival time increased over the period from 1973 to 2000. No differences were seen in the distribution of stage or age at diagnosis among time periods. Conclusion: PNETs are uncommon neoplasms but the incidence may be increasing. Age, grade, stage, and functional status predict survival in patients with PNETs. Survival has improved over time, but this is not explained by earlier diagnosis or stage migration.
引用
收藏
页码:1727 / 1733
页数:7
相关论文
共 31 条
  • [1] Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
    Aparicio, T
    Ducreux, M
    Baudin, E
    Sabourin, JC
    De Baere, T
    Mitry, E
    Schlumberger, M
    Rougier, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (08) : 1014 - 1019
  • [2] NEUROENDOCRINE TUMORS - A EUROPEAN VIEW
    BUCHANAN, KD
    JOHNSTON, CF
    OHARE, MMT
    ARDILL, JES
    SHAW, C
    COLLINS, JSA
    WATSON, RGP
    ATKINSON, AB
    HADDEN, DR
    KENNEDY, TL
    SLOAN, JM
    [J]. AMERICAN JOURNAL OF MEDICINE, 1986, 81 (6B) : 14 - 22
  • [3] CARRIAGA MT, 1995, CANCER-AM CANCER SOC, V75, P171, DOI 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO
  • [4] 2-2
  • [5] CUBILLA AL, 1975, ARCH PATHOL, V99, P204
  • [6] Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine turnors
    Delaunoit, T
    Rubin, J
    Neczyporenko, F
    Erlichman, C
    Hobday, TJ
    [J]. MAYO CLINIC PROCEEDINGS, 2005, 80 (04) : 502 - 506
  • [7] NEURO-ENDOCRINE PANCREATIC TUMORS - CLINICAL FINDINGS IN A PROSPECTIVE-STUDY OF 84 PATIENTS
    ERIKSSON, B
    OBERG, K
    SKOGSEID, B
    [J]. ACTA ONCOLOGICA, 1989, 28 (03) : 373 - 377
  • [8] Differences in survival by histologic type of pancreatic cancer
    Fesinmeyer, MD
    Austin, MA
    Li, CI
    De Roos, AJ
    Bowen, DJ
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (07) : 1766 - 1773
  • [9] Fitzgerald TL, 2007, 2007 GASTR CANC S
  • [10] GRIMELIUS L, 1975, VIRCHOWS ARCH A, V365, P275